Natera

Natera develops genetic diagnostics built on cell-free DNA (cfDNA) testing, with the aim of detecting disease at its earliest stages. Its work spans oncology, women's health and organ health, and relies on a proprietary platform combining molecular biology, bioinformatics and artificial intelligence to achieve ultrasensitive molecular detection - reported down to a single molecule in a tube of blood. The technical domains in play include cfDNA testing, bioinformatics, AI, prenatal screening, cancer detection and transplant monitoring.

Three tests anchor the product line. Panorama is a non-invasive prenatal screening test for detecting genetic conditions during pregnancy. Signatera is a personalised, tumour-informed cfDNA test for molecular residual disease and recurrence monitoring in cancer. Prospera monitors organ transplant rejection using cfDNA analysis. Each is described as market-leading in its category.

The company's scientific credentials include more than 300 peer-reviewed publications supporting test performance. Its laboratories are CLIA-certified, ISO 13485-certified and CAP-accredited. Natera operates from Austin, Texas and San Carlos, California, and serves patients and healthcare providers worldwide.

The stated mission is to make personalised genetic testing and diagnostics part of the standard of care, enabling earlier and more targeted intervention. The work sits at the intersection of clinical laboratory science, genomics and applied machine learning.